Northeast Investment Management Purchases 3,304 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Northeast Investment Management increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 3.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,474 shares of the medical equipment provider's stock after buying an additional 3,304 shares during the quarter. Intuitive Surgical accounts for 2.1% of Northeast Investment Management's portfolio, making the stock its 13th biggest holding. Northeast Investment Management's holdings in Intuitive Surgical were worth $45,800,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Intuitive Surgical by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock valued at $16,813,478,000 after purchasing an additional 360,591 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Intuitive Surgical by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider's stock valued at $4,039,200,000 after purchasing an additional 243,802 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Intuitive Surgical by 1.8% during the fourth quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider's stock valued at $2,541,356,000 after purchasing an additional 86,488 shares in the last quarter. Norges Bank acquired a new stake in Intuitive Surgical during the fourth quarter valued at approximately $2,401,493,000. Finally, Invesco Ltd. boosted its holdings in Intuitive Surgical by 7.7% during the fourth quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider's stock valued at $2,165,184,000 after purchasing an additional 295,025 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Gary Loeb sold 1,700 shares of the stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $513.18, for a total value of $872,406.00. Following the completion of the transaction, the executive vice president now owns 2,245 shares of the company's stock, valued at $1,152,089.10. This represents a 43.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction on Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the transaction, the executive vice president now directly owns 5,224 shares of the company's stock, valued at $2,695,113.84. This represents a 3.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,998 shares of company stock valued at $2,611,577. 0.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Robert W. Baird cut their target price on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Evercore ISI cut their target price on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research note on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and issued a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Barclays cut their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Finally, Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and an average price target of $588.95.

Intuitive Surgical Trading Down 1.8%

Shares of ISRG stock traded down $9.41 on Thursday, hitting $513.00. The stock had a trading volume of 2,390,381 shares, compared to its average volume of 1,668,728. Intuitive Surgical, Inc. has a twelve month low of $413.82 and a twelve month high of $616.00. The firm has a market cap of $183.87 billion, a P/E ratio of 80.03, a PEG ratio of 5.85 and a beta of 1.67. The company has a fifty day moving average price of $525.48 and a two-hundred day moving average price of $538.67.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same quarter in the previous year, the business earned $1.50 EPS. On average, analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.